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Introduction
The clinical use of siRNA therapeutics for the treatment of 
neurodegenerative disease is limited by a lack of reliable and 
nontoxic delivery routes to the central nervous system (CNS). 
siRNAs do not cross the blood–brain barrier and must therefore 
be directly injected or infused into the cerebrospinal fluid (CSF) 
or brain.1–4 However, many neurodegenerative disorders affect 
multiple regions of the brain, particularly the striatum and cor-
tex, requiring broad distribution from the site of administration.5 
Unmodified siRNAs directly injected into the brain are rapidly 
degraded or cleared from the CSF6 and continuous, large dose 
infusions are required to achieve local gene silencing.4,7 Typical 
lipid- and polymer-based siRNA formulations that improve cellu-
lar uptake show pronounced toxicity and inflammatory response 
when administered in the brain.8–10
We recently reported that cholesterol-conjugated hydro-
phobically modified siRNAs (Chol-hsiRNAs) efficiently silence 
Huntingtin (Htt) mRNA when injected directly into the striatum.11 
However, these compounds exhibit a steep gradient of diffusion 
from the injection site. This limits the utility of this platform in 
larger brains, and thus, its potential as a therapeutic modality. 
We explored if conjugation to less hydrophobic, brain-enriched 
lipids could improve siRNA distribution and minimize immuno-
genicity in vivo. Here, for the first time, we report the synthesis, 
and in vitro and in vivo efficacy, of a docosahexaenoic acid-
hsiRNA conjugate (DHA-hsiRNA) targeting Htt mRNA.
DHA is an omega-3 fatty acid and the principal fatty 
acid in the mammalian brain. DHA and its metabolites 
are involved in a variety of essential biological processes, 
including neurogenesis and neurotransmission.12 In the 
brain, DHA is primarily found esterified into the phospho-
lipid membranes of neural cells.13,14 DHA-containing lipids 
are substrates for hydrolyzing and oxidative enzymes (e.g., 
cyclooxygenase and lipooxygenase), which are capable of 
generating a range of potent neuroprotective metabolites, 
including neuroprotectin and resolvin.15–17 Orally adminis-
tered omega-3 fatty acids have shown anti-inflammatory 
and neuroprotective properties in the clinic.18 This is of par-
ticular interest from an RNAi perspective, where immune 
response and toxicity are major concerns.19 Polyunsatu-
rated fatty acids have also been investigated for potential 
antitumor effects, either alone or conjugated to chemother-
apeutic drugs.20,21
There are two previous reports of polyunsaturated fatty acid 
conjugation to therapeutic RNAs. Willibald et al. conjugated 
an anandamide to a partially modified siRNA, demonstrating 
mRNA silencing in human immune B (BJAB) and rat baso-
philic leukemia (RBL-2H3) cells in vitro.22 Felber et al. synthe-
sized FANA-modified antisense oligonucleotides conjugated 
to docosanoic acid, DHA, and cholesterol. These conjugates 
showed marginal activity in human prostrate cancer (PC-3) 
cells and were completely inhibited in the presence of 20% 
serum.23 These compounds were not tested in primary cells 
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The use of siRNA-based therapies for the treatment of neurodegenerative disease requires efficient, nontoxic distribution to the 
affected brain parenchyma, notably the striatum and cortex. Here, we describe the synthesis and activity of a fully chemically modified 
siRNA that is directly conjugated to docosahexaenoic acid (DHA), the most abundant polyunsaturated fatty acid in the mammalian 
brain. DHA conjugation enables enhanced siRNA retention throughout both the ipsilateral striatum and cortex following a single, 
intrastriatal injection (ranging from 6–60 μg). Within these tissues, DHA conjugation promotes internalization by both neurons and 
astrocytes. We demonstrate efficient and specific silencing of Huntingtin mRNA expression in both the ipsilateral striatum (up to 73%) 
and cortex (up to 51%) after 1 week. Moreover, following a bilateral intrastriatal injection (60 μg), we achieve up to 80% silencing of 
a secondary target, Cyclophilin B, at both the mRNA and protein level. Importantly, DHA-hsiRNAs do not induce neural cell death or 
measurable innate immune activation following administration of concentrations over 20 times above the efficacious dose. Thus, DHA 
conjugation is a novel strategy for improving siRNA activity in mouse brain, with potential to act as a new therapeutic platform for the 
treatment of neurodegenerative disorders.
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or animals, supporting the notion that compound behavior in 
transformed cell lines is not necessarily predictive of com-
pound distribution and activity in vivo.
The main objective of this study was to perform a compre-
hensive and systematic analysis of the efficacy, distribution, 
and toxicity of a DHA-hsiRNA conjugate in primary cortical 
neurons as well as in mouse brain.
Results
Design and synthesis of DHA-hsiRNA
To evaluate the impact of DHA on siRNA distribution in 
the brain, we used a previously identified functional siRNA 
sequence targeting both human and mouse Huntingtin (Htt) 
mRNA.11 This compound is an asymmetric siRNA composed 
of a 20-nucleotide antisense (guide) strand and a 15-nucle-
otide sense (passenger) strand.24 This oligonucleotide is 
stabilized with alternating 2′-O-methyl and 2′-fluoro sugar 
modifications using a variant of a pattern first described 
by the Allerson et al.25 These extensive modifications are 
essential for the evaluation of conjugate-mediated delivery in 
vivo, as partially modified or unmodified siRNAs are rapidly 
degraded and cleared from the circulation and brain, limit-
ing the ability to evaluate the conjugate’s RNAi activity (Has-
sler et al., 2016, manuscript submitted). The backbone of the 
terminal nucleotides is fully phosphorothioated to enhance 
stability against exonuclease-mediated degradation and to 
promote cellular internalization through a mechanism simi-
lar to that of antisense oligonucleotides (Figure 1a).26 The 
DHA moiety was conjugated through a commercially avail-
able C7 linker27 to the 3′-end of the sense strand via an amide 
bond (Figure 1b). Previous studies have identified the 3′-end 
of the sense strand to be an optimal position for conjugate 
attachment, with minimal effect on siRNA-RISC (intracellular 
RNA-induced silencing complex) loading.28–30 DHA-hsiRNA 
conjugates were synthesized on functionalized solid support 
bearing the DHA moiety (40 µmol/g) following standard solid-
phase synthesis and deprotection protocols (see Materials 
and Methods). Newly synthesized oligonucleotides were 
purified by high-performance liquid chromatography and 
characterized by liquid chromatography–mass spectrometry 
(LC–MS) (Supplementary Figure S1). All oligonucleotide 
sequences and chemical modification patterns used in this 
study are presented in Supplementary Table S1.
DHA-hsiRNAHTT is internalized in primary cortical 
neurons and shows potent Htt mRNA silencing
For all siRNA studies, we applied the fully chemically modified 
scaffold described by Hassler et al. (2016, manuscript sub-
mitted) to a hyper-functional Htt-targeting siRNA sequence 
previously identified and validated in our lab ( Supplementary 
Table S1).11
We first analyzed and compared the live cell uptake kinet-
ics of Chol-hsiRNAHTT and DHA-hsiRNAHTT in primary cortical 
neurons from wild-type (C57BL6) mice, using confocal imag-
ing (Figure 2a). While hsiRNAHTT rapidly associates with the 
cellular membrane (within minutes)11 and exhibits diffuse cyto-
plasmic staining, DHA-hsiRNAHTT shows slower uptake kinet-
ics to cytoplasmic foci with no detectable membrane binding. 
During early time points (of 4–6 hours) significant amounts 
of Chol-hsiRNAHTT are detected inside the cells, while levels 
of internalized DHA-hsiRNAHTT are minimal. Interestingly, 
the overall level of DHA-hsiRNAHTT neuronal accumulation at 
72 hours is comparable with that of Chol-hsiRNAHTT, result-
ing in similar levels of Htt silencing (Figure 2b). A secondary 
DHA-hsiRNA compound targeting cyclophilin B (Ppib) was 
evaluated to assess generality. After 1 week, DHA-hsiRNAPPIB 
silences Ppib mRNA by 75% in mouse primary cortical 
neurons (Supplementary Figure S2). A DHA-conjugated 
hsiRNA containing a scrambled, nontargeting sequence had 
no effect on Ppib mRNA expression (Supplementary Figure 
S2). Nonconjugated hsiRNAs have modest efficacy in vitro, 
likely due to residual internalization by the single-stranded 
phosphorothioate tail, in a mechanism similar to that of con-
ventional antisense oligonucleotides (Supplementary Figure 
S3). However, DHA conjugation results in enhancement of 
retention, distribution, and efficacy in mouse brain (vide infra).
To evaluate the impact of the bioconjugate on overall hsiRNA 
hydrophobicity, we compared the retention times of DHA-
hsiRNAHTT and Chol-hsiRNAHTT using reverse phase chroma-
tography (using a C8 modified column and triethylammonium 
acetate/acetonitrile eluents).31,32 We observed that DHA-hsiR-
NAHTT eluted at 8.5 minutes while Chol-hsiRNAHTT eluted at 11.8 
minutes under these conditions, suggesting that DHA-hsiR-
NAHTT is significantly less hydrophobic than cholesterol (Figure 
2c, see Materials and Methods). This finding indicates that over-
all hsiRNA hydrophobicity can be strongly affected by the linked 
conjugate. While DHA- and Chol-hsiRNAHTT conjugates have 
comparable activity in primary cortical neurons, we hypoth-
esized that the reduction in overall compound hydrophobicity 
may improve pharmacokinetic properties in vivo in mouse brain.
DHA-hsiRNAHTT shows widespread distribution in the 
mouse brain following intrastriatal injection
Next, we evaluated the bio-distribution and neural cell uptake 
of Chol-hsiRNAHTT and DHA-hsiRNAHTT in mouse brain. When 
administered directly via a single intrastriatal injection, Cy3-
labeled Chol-hsiRNAHTT was primarily detected on the ipsilat-
eral (injected) side of the brain (Figure 3). There is a steep 
gradient in distribution from the site of injection, however, with 
little detectable fluorescence present in the cortex or con-
tralateral (noninjected) striatum (Figure 3). Chol-hsiRNAHTT 
retention in the striatum may result from strong hydrophobic 
interactions with lipid-rich substructures (e.g. myelin-coated 
nerve bundles) in this region (Figure 4, unfilled arrows). 
Indeed, by high-resolution fluorescent microscopy (63X), we 
observe that Chol-hsiRNAHTT mainly associates with hydro-
phobic myelin sheaths and appears to colocalize with striatal 
nerve bundles at the site of injection (Figure 4). Chol-hsiR-
NAHTT is effectively internalized by neurons (Figure 4), and 
also, but to a smaller extent, by astrocytes (Figure 4). In neu-
rons, Chol-hsiRNAHTT is primarily observed in the neuronal 
processes, but also in the perinuclear area, the site of action 
of siRNAs (Figure 4, filled arrows).33,34
DHA-hsiRNAHTT distributed more broadly than Chol-hsiR-
NAHTT to both the ipsilateral striatum and cortex (Figure 3). 
This effect was specific to the DHA conjugate, as hsiRNA 
attached to the carbon linker alone was rapidly cleared 
 (Figure 3). Although DHA-hsiRNAHTT also colocalizes with 
striatal nerve bundles, the pattern of distribution and neuronal 
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internalization significantly differs from Chol-hsiRNAHTT. 
In both striatal and cortical neurons, DHA-hsiRNAHTT appears 
to primarily localize in the perinuclear area (Figure 4). Fur-
thermore, the lower hydrophobicity of DHA-hsiRNAHTT com-
pared with Chol-hsiRNAHTT appears to promote spread 
throughout the extracellular matrix and interstitial fluid, 
enabling an improved diffusion from the site of injection 
throughout the injected hemisphere.
DHA-hsiRNAHTT demonstrates significant, durable Htt 
mRNA silencing in both striatum and cortex following an 
intrastriatal injection
Given the broad distribution of DHA-conjugated hsiRNAs in 
the brain, we wanted to evaluate its ability to induce gene 
silencing in vivo. Wild-type mice (FVB/NJ) were injected with 
artificial CSF, a nontargeting control hsiRNA (DHA-hsiR-
NANTC, 25 µg), or DHA-hsiRNAHTT (6–25 µg), into the right 
striatum (n = 8 per group). After 5 days, levels of Htt mRNA 
expression were measured by QuantiGene assay, normalized 
to a housekeeping gene (Ppib) and presented as percentage 
of an untreated control.35 We observed dose-dependent Htt 
silencing in both the striatum (up to 73%) and cortex (up to 
51%) (Figure 5a,b). This degree of silencing in both cortex 
and striatum is consistent with the observed wide distribution 
pattern (Figure 3). While Chol-hsiRNAHTT Htt silencing was 
equally as effective in the striatum, there was no statistically 
significant Htt knockdown observed in the cortex (data not 
shown). We observe similar levels of silencing of a secondary 
gene target using this chemistry platform with a Cyclophilin 
B-targeting DHA-hsiRNA (DHA-hsiRNAPPIB Supplementary 
Figure S4 and Supplementary Figure S5). A bilateral, 60 
µg intrastriatal injection was performed and samples were 
collected for quantification of mRNA (QuantiGene) and pro-
tein expression. We observed robust Ppib silencing at both 
the mRNA and protein level, indicating that bilateral injection 
provides a simple and immediate ability to modulate gene 
Figure 1  Chemical structures and synthesis of hydrophobically modified siRNAs (hsiRNAs). (a) Fully chemically stabilized hsiRNA 
with either docosahexaenoic acid (DHA) or cholesterol (Chol) bioconjugates at the 3′-end of the sense strand. Molecular models of hsiRNA 
represented to scale using PyMOL. The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. (b) Solid-phase synthesis of 
DHA-conjugated hsiRNA. Htt, Huntingtin.
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expression in whole mouse striatum (Supplementary  Figure 
S4 and Supplementary Figure S5). We directly compared 
the levels of accumulation of a nonconjugated hsiRNA with 
a DHA-conjugated hsiRNA in both the striatum and cortex, 
using a quantitative peptide nucleic acid (PNA) hybridization 
assay.36 DHA improved retention in the striatum by ~10-fold, 
increasing retention from ~2 ng/mg tissue to ~18 ng/mg tissue 
(Figure 5c). DHA conjugation also improved retention in the 
cortex (~3.9 ng/mg tissue) compared with a nonconjugated 
hsiRNA, which accumulated to a lesser extent (~0.75 ng/mg 
tissue) (Figure 5d). This background retention of nonconju-
gated hsiRNA is likely a result of internalization mediated by 
the single-stranded phosphorothioated tail, described previ-
ously for antisense oligonucleotides. The level of retention 
correlated well with efficacy, as an unconjugated hsiRNA is 
only capable of achieving 50% Htt silencing in the striatum, 
with no detectable activity in the cortex following a single 
intrastriatal injection (12 µg, Figure 5e).
To evaluate the duration of effect, Htt silencing following a 
single, 12 µg DHA-hsiRNAHTT injection was measured at 7, 
14, and 28-day timepoints. The level of Htt silencing reduced 
over time, from ~60% at 7 days to 24% after 28 days. The 7 
and 14-day timepoints were significant assuming a nonpara-
metric distribution using a one-way analysis of variance with 
Dunns multiplicity correction (Figure 5e).
Figure 2 DHA-hsiRNA shows slow neuronal uptake, equivalent Huntingtin (Htt) mRNA silencing, and reduced hydrophobicity 
compared with Chol-hsiRNA. (a) Primary cortical neurons were incubated with Cy3-DHA-hsiRNAHTT and Cy3-Chol-hsiRNAHTT (0.5 µmol/l) 
for 0–72 hours. Images obtained with Leica inverted microscope (63×). Nuclei (Hoechst), blue; hsiRNA (Cy3), red. (b) Primary cortical neurons 
were incubated with Cy3-DHA-hsiRNAHTT and Chol-hsiRNAHTT at concentrations shown for 1 week. Level of huntingtin mRNA was measured 
using QuantiGene (Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), and presented as percent of untreated control (n = 3, 
mean ± SD). UNT, untreated cells. (c) High-performance liquid chromatography (HPLC) traces of DHA-hsiRNAHTT and Chol-hsiRNAHTT 
following reverse phase chromatography (C8 column). Htt, Huntingtin; DHA, docosahexaenoic acid; DHA-hsiRNA, docosahexaenoic acid-
hsiRNA conjugate; Chol-hsiRNA, cholesterol-hsiRNA conjugate.
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Figure 3 DHA-hsiRNAHTT shows widespread distribution in 
the mouse brain. aCSF, Cy3-C7linker-hsiRNAHTT, Cy3-Chol-
hsiRNAHTT, Cy3-DHA-hsiRNAHTT were administered by unilateral 
intrastriatal injection (25 µg, 2 µl) and fluorescent images acquired 
by a Leica tiling microscope after 24 hours. Images consist of 
tiled-array of coronal sections at 10× magnification acquired 
with equivalent exposure and contrast settings. aCSF, artificial 
cerebrospinal fluid;  Chol-hsiRNA, cholesterol-hsiRNA conjugate; 
DHA, docosahexaenoic acid; DHA-hsiRNA, docosahexaenoic acid-
hsiRNA conjugate; Htt, Huntingtin.
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DHA-hsiRNAHTT does not induce measurable immune 
stimulation or adverse impact on neuronal viability over 
a broad dosage range
One of the major hurdles in the development of novel cen-
tral nervous system-directed delivery technologies is dose-
limiting toxicity. Typical lipid- and polymer-based siRNA 
formulations that improve pharmacokinetic properties 
when administered systemically exhibit pronounced toxicity 
and inflammatory response in the brain.10,19 To evaluate the 
safety of DHA-hsiRNA conjugates, we monitored changes 
in the expression of ionized calcium-binding adapter mole-
cule 1 (IBA1) and dopamine- and cAMP-regulated neuronal 
phosphoprotein (DARPP-32), markers for innate immune 
stimulation and neuronal integrity, respectively. IBA-1 is a 
microglial-specific cell marker up-regulated following neu-
ron injury, and IBA-1 staining is used to estimate levels of 
microglial activation following hsiRNA treatment by distin-
guishing between resting and activated microglia based on 
morphology.37–39 DARPP-32 is an established marker for 
striatal dopamine receptor activity and neuron viability.40
Previously, we have shown that partially modified Chol-hsiR-
NAs have no impact on DARPP-32 levels (neuronal viability) 
at efficacious levels, but induce a slight increase in the level 
of activated microglia using an IBA-1 marker.11 When choles-
terol was conjugated to fully modified scaffold utilized herein, 
severe toxicity was observed at doses higher than 25 µg, caus-
ing mortality in ~30% of injected animals (data not shown). This 
pronounced increase in toxicity is attributed to poor distribu-
tion from the site of injection, with excess accumulation of the 
hydrophobic, chemically stabilized hsiRNA causing neuronal 
loss, consistent with the hypothesis that a high local compound 
concentration is toxic within brain tissues.
To evaluate the toxicity of DHA-hsiRNA in vivo, animals 
were injected with a broad range of DHA-hsiRNA concentra-
tions (25–200 µg). Given the solubility limit of DHA-hsiRNA (10 
mmol/l in artificial CSF (aCSF)) and the injection volume (2 µl), 
Figure 4 DHA-hsiRNA exhibits clear neuronal localization in both the cortex and striatum following a unilateral intrastriatal injection. 
Cy3-Chol-hsiRNAHTT or Cy3-DHA-hsiRNAHTT were administered by unilateral intrastriatal injection (25 µg, 2 µl) and fluorescent images 
acquired at 63× magnification by a Leica DMI6,000B microscope after 24 hours. Left two columns: ipsilateral striatum. Right two columns: 
ipsilateral cortex. Filled arrows indicate colocalization with nerve bundles. Unfilled arrows indicate subcellular localization to the perinuclear 
space. Enlarged inlets from merged image depicting neuronal uptake in the striatum (left) and cortex (right) for both Cy3-Chol-hsiRNAHTT 
and Cy3-DHA-hsiRNAHTT (bottom panels). Nuclei (DAPI), blue; NeuN, green; GFAP, magenta; Cy3-hsiRNA, red. Scale bar = 20 µm. DHA, 
docosahexaenoic acid; DHA-hsiRNA, docosahexaenoic acid-hsiRNA conjugate; Htt, Huntingtin.
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200 µg is the highest possible dose that can be administered 
intrastriatally, and 25 µg is fourfold higher than what is required 
for detectible silencing activity (Figure 5). We observed no 
reduction in DARPP-32 levels (Figure 6a) or significant eleva-
tion of activated microglia (Figure 6b) in coronal brain sections 
of mice treated at the highest dose level. Moreover, all injected 
animals appeared normal, with no signs of distress or toxicity. 
These results indicate that administration of DHA-hsiRNA has 
no measureable impact on neuronal integrity or innate immune 
system activation at the dose levels tested (Figure 6).
Discussion
Direct conjugation of siRNA to small, bioactive ligands has 
the potential to allow efficient, targeted tissue delivery, which 
remains an outstanding challenge in the field of therapeutic 
RNAi. This strategy is particularly promising for brain appli-
cations, where conventional siRNA carriers (including lipid-
based formulations, polymers, nanoparticles, or dendrimers) 
are not generally well tolerated.8–10 Here, we report that direct 
conjugation of DHA to a fully chemically stabilized siRNA 
scaffold shows significant tissue retention with wide distribu-
tion and robust efficacy in mouse brain. Notably, DHA-hsiRNA 
conjugates do not elicit measurable microglial activation and 
have no adverse effect on neuronal viability at concentrations 
over 20-fold higher than the efficacious dose.
DHA-hsiRNA alleviates one of the major obstacles to neu-
rological applications of siRNA, which is achieving widespread 
distribution to brain parenchyma. Following a direct intrastriatal 
injection, DHA-hsiRNA distributed broadly throughout the stria-
tum and cortex of the injected hemisphere, with no dramatic 
compound accumulation around the site of injection (a typical 
feature of Chol-hsiRNA). We observed DHA-hsiRNA colocal-
ization with both neuronal (neuronal nuclei antigen (NeuN)) and 
astrocyte (glial fibrillary acidic protein (GFAP)) markers. DHA-
hsiRNA clearly localized to the perinuclear space in both stria-
tal and cortical neurons (the cytoplasmic site of active RNAi).
DHA-hsiRNA accumulates to a functional degree in both 
the striatum and cortex after a single, intrastriatal injection. 
Htt silencing is achieved at concentrations as low as 6 µg 
(~25% silencing) in the striatum and 12 µg (~30% silencing) 
in the cortex. A maximal knockdown of 70–80% was seen 
following administration of 25 µg in the striatum. Duration of 
effect studies reveal persistent Htt mRNA silencing in mouse 
striatum up to 4 weeks after a single, 12 µg intrastriatal 
injection. We observed comparable levels of gene silencing 
of a secondary target, Ppib, with the DHA-hsiRNA chem-
istry platform. We utilized a bilateral intrastriatal injection 
of DHA-hsiRNAPPIB to quantify the reduction in Ppib mRNA 
and protein levels throughout both hemispheres, achieving 
up to ~80% silencing in the striatum. These results suggest 
that DHA-hsiRNA has immediate potential to modulate gene 
expression in animal models of neurodegenerative disorders.
Figure 5 DHA-hsiRNAHTT efficacy and duration of effect following intrastriatal injection. DHA-hsiRNA or nonconjugated hsiRNA were 
unilaterally injected into the striatum of wild-type mice. Punch biopsies of the striatum (a,e) and cortex (b,e) were collected after 5 days. For 
duration of effect e, punch biopsies of the striatum were collected at times shown. Level of Htt mRNA was measured using QuantiGene® 
(Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), and presented as percentage of untreated control (n = 8 mice, mean ± 
SD). NTC, nontargeting control; aCSF, artificial cerebrospinal fluid (d,e) Plot showing tissue concentrations of DHA-hsiRNAHTT guide strand 
measured by PNA hybridization from the ipsilateral striatum (c) or cortex (d). (*P < 0.05, ** P < 0.01, ***P < 0.001, ****P < 0.0001). DHA, 
docosahexaenoic acid; DHA-hsiRNA, docosahexaenoic acid-hsiRNA conjugate; PNA, peptide nucleic acid; Htt, Huntingtin.
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We were encouraged by the results of the pilot safety study. 
Comparing increasing concentrations of fully chemically 
modified DHA-hsiRNA and Chol-hsiRNA, we found that Chol-
hsiRNA induces significant loss of brain matter and occasion-
ally animal morbidity at doses above 25 µg (data not shown). In 
contrast, animals injected with 200 µg of DHA-hsiRNA appear 
healthy, with normal brain morphology. 200 µg is the maximal 
amount that can be delivered intrastriatally, given the solubil-
ity limit of DHA-hsiRNA. The acute toxicity observed following 
Chol-hsiRNA administration is likely due to elevated compound 
retention around the site of injection, as a less stable, par-
tially modified Chol-hsiRNA has a minimal effect on neuronal 
viability, following direct intrastriatal injection.11 The reduced 
hydrophobicity and broad distribution of fully chemically modi-
fied DHA-hsiRNA precludes accumulation around the site of 
injection, and likely supports its high tolerance and safety in 
vivo. This chemistry may support an even wider therapeutic 
index following other clinically feasible routes of administration 
(e.g., intrathecal, intracerebroventricular, or systemic intrave-
nous), administration of higher doses, or through multiple-dose 
regimens. For instance, antisense oligonucleotides delivered 
through a bolus intrathecal administration in rodents are dosed 
at up to 600 µg total.41 A long-term safety study, including mea-
surement of cytokine levels to further assess immunogenicity, 
as well as aspartate transaminase (AST)/ alanine transami-
nase (ALT) blood ratios to determine hepatotoxicity, would cor-
roborate the results presented in this study.
The mechanism behind the safety profile of DHA-
hsiRNA is unknown. A comprehensive understanding of the 
DHA-hsiRNA safety profile is essential for clinical develop-
ment of these compounds for therapeutic applications. DHA 
is highly abundant in the mammalian brain, of which DHA 
and related polyunsaturated fatty acids comprise >50% of 
neural cell phospholipid membranes. DHA metabolites are 
involved in signal transduction, cell survival, and alleviating 
neuroinflammation.15 It is possible that the DHA moieties 
from DHA-hsiRNA conjugates may enter into endogenous 
fatty acid trafficking, phospholipid biosynthesis, and meta-
bolic pathways of neural cells, contributing to tissue health 
and overall compound safety.42–44
DHA is a single representative of a class of biologically 
active polyunsaturated fatty acids. While saturated or mono-
unsaturated lipids have been extensively explored for siRNA 
delivery,45–48 polyunsaturated fatty acid-siRNA conjugates are 
less well described. It would be interesting to investigate the 
tissue distribution and efficacy of other polyunsaturated fatty 
acid-hsiRNA conjugates, such as eicosapentaenoic acid. 
It would also be intriguing to determine whether these types 
of conjugates can enhance the efficacy of other classes of 
therapeutic oligonucleotides, like antisense or splice-switch-
ing oligonucleotides. We believe that it is likely, as long the 
oligonucleotide modality is chemically stabilized sufficiently 
to be stable in tissue for extended periods of time.
In this study, we targeted Htt, the causative gene of Hun-
tington’s disease. Currently prescribed small molecule drugs 
for genetically defined neurodegenerative diseases, such 
as Huntington’s disease, seek to treat disease symptoms 
without addressing the underlying genetic cause. A major 
Figure 6 DHA-hsiRNAHTT shows no impact on neuronal integrity or innate immune activation at ~20-fold higher concentrations than 
what is required for activity. DHA-hsiRNAHTT was administered by unilateral intrastriatal injection. Brains were collected after 5 days, fixed, 
sectioned, and stained with antibodies against DARPP-32, a marker for spiny medium neurons, or IBA-1, a marker for microglia. (a) Data 
represented as total number of DARPP-32 positive neurons per tissue section (n = 3 mice, mean ± SD). (b) Representative images of DARPP-
32 staining. (c) Data represented as total number of activated microglia (n = 3 mice, mean ± SD). (d) Representative images of IBA-1 staining. 
IBA1, ionized calcium-binding adapter molecule 1 DHA, docosahexaenoic acid; DHA-hsiRNA, docosahexaenoic acid-hsiRNA conjugate; 
PNA, peptide nucleic acid; Htt, Huntingtin.
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advantage of RNAi-based therapeutics is that it permits spe-
cific targeting of the gene(s) underlining the clinical pathol-
ogy. It has been shown that transient modulation of both 
wild-type and mutant Htt alleles were sufficient to support 
reversal of disease phenotype. An antisense compound tar-
geting both alleles has recently advanced into clinical trials.41 
DHA-hsiRNAHTT demonstrates robust and durable silenc-
ing in both striatum and cortex, the brain regions primarily 
affected in Huntington’s disease. The data presented here 
describe a promising novel platform for modulation of gene 
expression in vivo in the brain, paving the path toward better 
therapeutics for the treatment of dominant and hereditable 
neurodegenerative diseases including Huntington’s disease.
Materials and methods
Materials. DHA was from MP Biomedicals (Solon, OH) and 
1-O-DMT-6-N−Fmoc-2-hydroxymethylhexane from Toronto 
Research Chemicals (Ontario, Canada). RNA synthesis 
reagents and controlled pore glass functionalized with long 
chain alkyl amine (LCAA-CPG) were obtained from Chem-
Genes (Wilmington, MA). Quasar 570 CE phosphoramidite 
(Cy3) was purchased from Gene Pharma (Shanghai, China).
Preparation of amine-bearing CPG. A functionalized CPG (3, 
Figure 1) was prepared and used for the solid-phase conju-
gation of DHA. First, LCAA-CPG (particle size 125–177 µm, 
pore diameter 500 Å and primary amino loading 145 µmol/g) 
was activated and dried over night according to published 
protocols.49 Then, the commercially available 1-O-DMT-6-
N−Fmoc-2-hydroxymethylhexane was converted to succi-
nate and loaded on CPG following a reported procedure to 
afford 2.50 The linker loading was determined by DMT assay 
to be around 50 µmol/g. Subsequently, the Fmoc group was 
removed from 2 using a solution of 20% piperidine in dimeth-
ylformamide for 15 minutes. This procedure was repeated 
twice to ensure complete deprotection of the Fmoc group. 
The amine-bearing CPG 3 was filtered off and washed suc-
cessively with CH2CI2, ACN, and ether then dried under 
vacuum.
DHA coupling. 38 mg of DHA (40.3 µl, 115.6 µmol) was trans-
ferred to a 5 ml flask and dissolved in 3 ml of dry dimethyl for-
mamide (DMF). The solution was degassed and kept under 
argon. Then 11.4 mg (30 µmol) of 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexa-
fluorophosphate (HATU) was added to the flask and the 
solution was stirred for 3 minutes. Five eq. of Diisopropyle-
thylamine (DIEA) was added to the solution followed by 
600 mg (30 µmol, loading 50 µmol/g) of amine-bearing CPG 
3. The flask was sealed and rocked gently at room tempera-
ture. After 12 hours, the CPG was filtered off and washed 
successively with CH2CI2, acetonitrile (ACN), and ether, then 
dried under vacuum.
Synthesis of oligonucleotides. Oligonucleotides were synthe-
sized on an Expedite ABI DNA/RNA Synthesizer following 
standard protocols. Each synthesis was done at a 1-µmole 
scale using DHA-conjugated CPG for the sense (see above) 
and a Unylinker terminus (ChemGenes) for the antisense 
strands. Phosphoramidites were prepared as 0.15 mol/l 
solutions for 2′-O-methyl (ChemGenes) and Cy3 (Gene 
Pharma) and 0.13 mol/l for 2′-fluoro (BioAutomation, Irving, 
Texas) in ACN. 5-(Ethylthio)-1H-tetrazole (ETT) 0.25 mol/l 
in ACN was used as coupling activator. Detritylations were 
performed using 3% dichloroacetic acid in CH2Cl2 for 80 sec-
onds and capping was done with a 16% N-methylimidazole 
in THF (CAP A) and acetic anhydride:pyridine:THF, (1:2:2, 
v/v/v) (CAP B) for 15 seconds. Sulfurizations were carried 
out with 0.1 mol/l solution of ((dimethylamino-methylidene)
amino)-H-1,2,4-dithiazaoline-3-thione (DDTT) in ACN for 
3 minutes. Oxidation was performed using 0.1 mol/l iodine in 
pyridine:water:THF (1:2:10, v/v/v). Phosphoramidite coupling 
times were 350 seconds for all amidites.
Deprotection and purification of oligonucleotides. Both sense 
and antisense strands were cleaved and deprotected using 
1 ml of 40% aq. methylamine at 65°C for 10 minutes. The oli-
gonucleotide solutions were then cooled in a freezer for a few 
minutes and dried under vacuum in a Speedvac. The result-
ing pellets were suspended in 10 ml of triethylammonium 
acetate buffer (0.1 mol/l, pH 7) and filtered through a 0.2 µm 
filter. The final purification of oligonucleotides was performed 
on an Agilent Prostar System (Agilent, Santa Clara, CA) 
equipped with a Hamilton HxSil C8 column (150 × 21.2) using 
the following conditions: buffer A: (0.1 mol/l, TEAA, PH 7), B: 
(ACN), gradient: 10% B, 90% A to 90% B, 10% A in 30 min-
utes, temperature: 55°C, flow rate: 20 ml/minutes. The pure 
oligonucleotides were collected and cation-exchanged on 
a HiTrap 5 ml SP HP column (GE Healthcare Life Sciences, 
Marlborough, MA) and lyophilized. The overall yields of DHA-
conjugated siRNAs were constantly above 60%.
LC–MS analysis of oligonucleotides. The identity of oligonu-
cleotides were established by LC–MS analysis on a Waters 
Q-TOF premier machine (Waters Corporation, Milford, 
MA) using following conditions: buffer A (15 mmol/l dibutyl-
amine/25 mmol/l hexafluoroisopropanol), buffer B (20% A 
in MeOH), column: xbidge OST C18 (Waters Corporation), 
2.5µm, gradient: 0–10 minutes (1% B-80% B), 10–13 min-
utes (80% B-80% B), 13.1 minutes (80% B-1% B), 13.1–18 
minutes (1% B-1% B). A sample LC–MS chromatogram of 
the DHA-conjugated siRNAs is shown in Supplementary 
Figure S1.
Preparation of primary neurons. Primary cortical neurons 
were isolated and cultured from FVB/NJ mouse embryos 
at embryonic day 15.5 as described previously.11 Briefly, the 
cortices from both embryonic brain hemispheres were dis-
sected, and a solution of papain and DNAse I (Worthington, 
Lakewood, NJ) in Hibernate E medium (Brainbits, Springfield, 
IL) was used to disrupt the extracellular matrix prior to tritura-
tion to a single-cell suspension using a fire-polished glass 
pipette. Cortical neurons were plated at 1 × 105 cells/well in a 
poly-L-lysine coated 96-well plate (Sigma, St. Louis, MO) in 
100 µl of NBActiv4 (Brainbits) supplemented with 1.5% fetal 
bovine serum (Sigma). The following day, the cellular media 
was supplemented with antimitotics to prevent growth of non-
neuronal cells (0.48 µl/ml UTP and 0.2402 µ/ml of FdUMP, 
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Sigma). Neurons were treated with oligonucleotides on day 
3 after plating.
Direct delivery (passive uptake) of oligonucleotides. Cells 
were plated in Dulbecco’s modified essential medium con-
taining 6% fetal bovine serum at 10,000 cells per well in 
96-well tissue culture plates. hsiRNA was diluted to twice the 
final concentration in OptiMEM (Gibco, Carlsbad, CA), and 
50 µl diluted hsiRNA was added to 50 µl of cells, resulting 
in 3% fetal bovine serum final. Cells were incubated for 72 
hours at 37°C and 5% CO2.
Confocal imaging. All confocal images were acquired with a 
CSU10B Spinning Disk Confocal System scan head (Sola-
mere Technology Group) mounted on a TE-200E2 inverted 
microscope (Nikon, Melville, NY) with a 60x Plan/APO oil lens 
and a Coolsnap HQ2 camera (Roper, Acton, MA). Images 
were processed using ImageJ (1.47v) software.
mRNA quantification in cells and tissue punches. mRNA was 
quantified from both cells and tissue punches using the Quan-
tiGene 2.0 Branched DNA (bDNA) Assay (Affymetrix, Santa 
Clara, CA) as described previously.35 Probe sets (Mouse Htt 
or Ppib, #SB-14,150 and #SB-10,002) were diluted and used 
according to the manufacturer’s recommended protocol. 
Briefly, tissue punches (5 mg) were homogenized in 300 µl 
of Homogenizing Buffer (Affymetrix) containing 2 µg/µl pro-
teinase K in 96-well plate format on a QIAGEN TissueLyser II 
and 40 µl of each lysate was added to a bDNA capture plate. 
Htt or Ppib probe sets (60 µl) were added to each well of the 
capture plate for a final volume of 100 µl. Signal was ampli-
fied according to the Affymetrix protocol. Luminescence was 
detected on a Tecan M1,000 luminometer.
Live cell imaging. To monitor live cell DHA- and Chol-hsiRNA 
uptake, primary cortical neurons were plated at a density of 
2 × 105 cells per poly-L-lysine coated, 35 mm glass-bottom 
dish. Cell nuclei were stained with NucBlue (Life Technolo-
gies, Carlsbad, CA) according to the manufacturer’s rec-
ommended protocol. Imaging was performed in phenol 
red-free NbActiv4 medium (Brainbits). Cells were treated 
with 0.5 µmol/l Cy3-labeled hsiRNA, and live cell imaging 
was performed over time. All live cell confocal images were 
acquired with a Zeiss confocal microscope, and images 
were processed using ImageJ (1.47v) software as described 
previously.
Stereotaxic injections and tissue collection. FVB/NJ male 
and female mice (6–8 weeks old) were deeply anesthetized 
with 1.2% Avertin (Sigma) and microinjected by stereotac-
tic placement into the right striatum (coordinates relative to 
bregma: 1.0 mm anterior, 2.0 mm lateral, and 3.0 mm ventral).
For efficacy studies, animals were injected unilaterally or 
bilaterally with 2 µl of artificial CSF (aCSF), DHA-hsiRNANTC 
(12.5 µg), and DHA-hsiRNAHTT (3.1, 6.3, 12.5, 25, or 60 µg) 
or the doses indicated for the toxicity studies. For efficacy 
studies n = 8 mice were injected per group, and for toxicity 
studies n = 3 mice were injected per group. Mice were eutha-
nized 5 days postinjection and brains harvested. For efficacy 
studies, three 300 µm coronal sections were collected and 
from each section, a 2 mm punch was taken from each side 
(injected and noninjected) and placed in RNA later (Ambion, 
Waltham, MA) for 24 hours at 4°C. Each punch was pro-
cessed as an individual sample for QuantiGene 2.0 assay 
analysis (Affymetrix), and averaged for a single animal point. 
For DARPP-32 assessment toxicity studies, animals were 
perfused with phosphate-buffered saline and 10% formalin 
solution, and postfixed for 24 hours. For microglial activation 
studies, brains were harvested after 6 hours or 5 days. Brains 
were sliced into 40 µm sections on the Leica 2,000T Vibra-
tome (Leica Biosystems, Buffalo Grove, IL) in ice cold PBS, 
and stored at 4ºC until immunostaining was carried out.
For biodistribution studies, mice were injected into the 
right striatum with 2 µl of aCSF, Cy3-Chol-hsiRNAHTT (25 µg) 
or Cy3-DHA-hsiRNAHTT (25 µg). After 48 hours, mice were 
euthanized and perfused with PBS and 10% formalin solu-
tion, and brains postfixed for 48 hours. Afterwards, brains 
were paraffin-embedded and sliced into 4 µm sections that 
were mounted on glass slides. All animal procedures were 
approved by the University of Massachusetts Medical School 
Institutional Animal Care and Use Committee (IACUC, proto-
col number A-2411).
PNA hybridization assay. Overall levels of hsiRNA guide 
(antisense) strand in mouse brain were quantified using a 
modified PNA hybridization assay. Tissue samples from 
the efficacy studies were lysed in MasterPure Tissue Lysis 
Solution (EpiCentre) in the presence of proteinase K (2 mg/
ml) (Invitrogen, #25530-049) and homogenized using a Tis-
sueLyser II (Qiagen), with roughly 10 mg tissue per 100 µl 
lysis solution. Sodium dodecyl sulfate from lysate was pre-
cipitated with KCl (3 mol/l) and pelleted at 5,000 g. hsiRNA 
present in the cleared supernatant was hybridized to a Cy3-
labeled PNA fully complementary to guide strand (PNABio, 
Thousand Oaks, CA) and injected into high-performance liq-
uid chromatography DNAPac PA100 anion exchange column 
(Thermo Fisher Scientific). Cy3 fluorescence was monitored 
and peaks integrated. Mobile phase for high-performance 
liquid chromatography was 50% water, 50% acetonitrile, 
25 mmol/l Tris-HCl (pH 8.5), and 1 mmol/l ethylenediamine-
tetraacetate. The salt gradient was 0–800 mmol/l NaClO4. 
For an internal calibration curve, a known amount of hsiRNA 
duplex was spiked into the tissue lysis solution.
Immunohistochemistry and immunofluorescence. For biodis-
tribution studies, tissue sections on glass slides were depar-
affinized by incubating samples twice for 8 minutes in Xylene. 
Sections were rehydrated by incubating samples in a series 
of ethanol dilutions (100, 95, and 80%), for 4 minutes each. 
Slides where then washed twice for 2 minutes with PBS.
NeuN and GFAP immunostaining was carried out after 
antigen retrieval by boiling tissue sections for 5 minutes in 
10 mmol/l Tris/ 1mmol/l ethylenediaminetetraacetate (pH 9.0) 
buffer, followed by 20 minutes incubation at room tempera-
ture. Sections were then washed for 5 minutes in PBS and 
blocked for 1 hour in 5% normal goat serum in PBS containing 
0.05% Tween 20 (PBST). Slides were washed for 5 minutes 
with PBST, and incubated with anti-mouse NeuN (1:1,000 
dilution) (Millipore, Billerica, MA) or anti-mouse GFAP (1:340) 
(Dako, Santa Clara, CA) primary antibody in PBST. Sections 
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were washed three times with PBST for 5 minutes, and incu-
bated with respective secondary antibody for 30 minutes in 
the dark. Secondary antibodies used were antimouse Alexa 
488 (1:1,000) (Life Technologies) and anti-rabbit Alexa 647 
(1:1,000 dilution) (Life Technologies). Slides were washed 
three times with PBST for 5 minutes and counterstained 
with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI) 
(250 ng/ml) (Molecular Probes, Life Technologies) in PBS for 
2 minutes followed by a wash in PBS for 2 minutes. Slides 
were mounted with mounting medium and coverslips and 
dried overnight in the cold room. Tiled-arrays of coronal sec-
tions were acquired on a Leica DM5500B microscope and 
high-resolution images at 63× acquired on a Leica DMI6000 
microscope, both microscopes were fitted with a DFC365 FX 
fluorescence camera.
For toxicity studies, 40 µm formalin-fixed sections were 
assessed for DARPP-32 and/or IBA1 immunostaining. A total 
of 9 sections per brain and 8 images per section (4 per hemi-
sphere) were evaluated. Sections for IBA-1 immunostaining 
were incubated in blocking solution (5% normal goat serum, 
1% bovine serum albumin, 0.2% Triton-X-100, and 0.03% 
hydrogen peroxide in PBS) for 1 hour, and then washed with 
PBS. Later, sections were incubated overnight at 4ºC in pri-
mary antibody, anti-Iba1 (1:500 dilution in blocking solution) 
(Wako, Richmond, VA). Sections were then stained with goat 
antirabbit secondary antibody (1:200 dilution) (Vector Labora-
tories, Burlingame, CA) for 1 hour. Slides were washed with 
PBS, and incubated with the Vectastain ABC Kit (Vector Labo-
ratories), followed by another PBS wash. IBA-1 was detected 
with the Metal Enhanced DAB Substrate Kit (Pierce, Dallas, 
TX). For DARPP32 staining, sections were incubated for 3 
minutes in 3% hydrogen peroxide, followed by 20 minutes in 
0.2% Triton-X-100. Samples were incubated in 1.5% normal 
goat serum in PBS for 4 hours, and thereafter incubated over-
night at 4ºC in DARPP32 primary antibody (1:10,000 dilution in 
1.5% normal goat serum) (Abcam, Cambridge, UK). Second-
ary antibody and detection steps were conducted as described 
for IBA-1 staining. Sections were mounted and cover-slipped. 
A Nikon Eclipse E600 microscope with a Nikon Digital Sight 
DSRi1 camera was used to visualize and acquire bright field 
images at 20x or 40x for counting and analysis. The number 
of DARPP-32-positive neurons was quantified manually using 
the cell counter plug-in on ImageJ for tracking and activated 
microglia was quantified by morphology of IBA1-positive cells. 
All sections were coded and randomized to enable blinded 
counting of both IBA1 and DARPP-32 positive cells. Coronal 
section images were acquired using a Coolscan V-ED LS50 
35 mm Film Scanner (Nikon).
Statistical analysis. Data were analyzed using GraphPad Prism 
6 software (GraphPad Software, San Diego, CA). Concentra-
tion-dependent IC50 curves were fitted using a log(inhibitor) 
versus response – variable slope (four parameters). The lower 
limit of the curve was set at zero, and the upper limit of the curve 
was set at 100. For each independent mouse experiment, the 
level of knockdown at each dose was normalized to the mean 
of the control group (the noninjected side of the PBS or artificial 
CSF groups). In vivo data were analyzed using nonparametric 
Kruskal-Wallis test of one-way analysis of variance with Dunn’s 
multiple comparisons test. Differences in all comparisons were 
considered significant at P-values ≤ 0.05 compared with the 
noninjected (contralateral) side of striatum for the NTC injected 
group. For microglial activation, significance was calculated 
using a parametric, unpaired, two-tailed t-test for comparison 
between dose groups.
Supplementary material
Figure S1. Representative LC-MS characterization of Cy3-
DHA-hsiRNAHTT.
Figure S2. DHA-hsiRNAPPIB silences Cyclophilin B (Ppib) 
mRNA in mouse primary cortical neurons.
Figure S3. Non-conjugated hsiRNAHTT exhibits modest 
Huntingtin (Htt) mRNA silencing in mouse primary cortical 
neurons.
Figure S4. DHA-hsiRNAPPIB silences Cyclophilin B (Ppib) 
mRNA in mouse striatum following a single intrastriatal 
 injection.
Figure S5. DHA-hsiRNAPPIB silences Cyclophilin B (PPIB) 
protein in mouse striatum following a single intrastriatal injection.
Table S1. Modified Oligonucleotide Sequences.
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